Aller au contenu principal

 Articles scientifiques

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

Auteurs : Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SAJ, Cunningham D, Peyrade F, Fruchart C, Arkenau HT, Genvresse I, Liu L, Köchert K, Shen K, Kneip C, Peña CE, Grevel J, Zhang J, Cisternas G, Reschke S, Granvil C, Awada A
Année : 2020
Journal : Mol Cancer Ther
Volume : 19
Pages : 468-478

Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.

Auteurs : Farhat F, Tarabaih M, Kanj A, Aoun M, Kattan J, Assi T, Awada A
Année : 2020
Journal : Anticancer Drugs
Volume : 31
Pages : 85-89

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.

Auteurs : Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem GE, Van Gestel D
Année : 2019
Journal : Cancers (Basel)
Volume : 11

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Auteurs : Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 5

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Auteurs : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Année : 2019
Journal : Support Care Cancer
Volume : 27
Pages : 1163-1170

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.

Auteurs : Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP
Année : 2019
Journal : Acta Clin Belg
Pages : 1-8

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Auteurs : Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, OShaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 397-404

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.

Auteurs : El Hachem G, Gombos A, Awada A
Année : 2019
Journal : F1000Res
Volume : 8

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).

Auteurs : Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 176
Pages : 607-615

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an <i>ESMO Open-Cancer Horizons</i> pro and con discussion.

Auteurs : Awada A, Gligorov J, Jerusalem G, Preusser M, Singer C, Zielinski C
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000565

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Auteurs : Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A
Année : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 420-423

Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives.

Auteurs : Kotecki N, Awada A
Année : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 439-444

Therapeutic management of malignant paragangliomas: an illustrative case and literature review.

Auteurs : Afani L, Errihani H, Awada A
Année : 2019
Journal : Pan Afr Med J
Volume : 32
Pages : 62

Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer.

Auteurs : Gombos A, Franzoi MA, Awada A
Année : 2019
Journal : Expert Opin Investig Drugs
Volume : 28
Pages : 617-627

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.

Auteurs : Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, Charpentier E, Emmons GT, Garcia-Ribas I, Paridaens R, Verweij J
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 383-393

Targeted therapy for breast cancer in older patients.

Auteurs : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Lago LD
Année : 2019
Journal : J Geriatr Oncol

Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies.

Auteurs : El Ali Z, Rottey S, Barthelemy P, Kotecki N, VAN Paemel R, Devrient D, Awada A, Gil T, Pannier D, Ryckewaert T, Waisse W, Clavier JB, Penel N, Vermassen T
Année : 2019
Journal : Anticancer Res
Volume : 39
Pages : 2993-3002

Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.

Auteurs : Kotecki N, Gombos A, Awada A
Année : 2019
Journal : Expert Rev Anticancer Ther
Volume : 19
Pages : 447-454

Promising Immuno-Oncology Treatments Beyond the 2018 Nobel Prize.

Auteurs : Castelo-Branco L, Silva IP, Canhão H, Awada A
Année : 2019
Journal : Acta Med Port
Volume : 32
Pages : 251-257

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Auteurs : Basaran G, Twelves C, Diéras V, Cortés J, Awada A
Année : 2018
Journal : Cancer Treat Rev
Volume : 63
Pages : 144-155